Brain Stimulation for Mild Cognitive Impairment
(miniSTIM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a form of brain stimulation called transcranial direct current stimulation (tDCS) to determine its effects on brain function and memory. The focus is on individuals with mild cognitive impairment (MCI), characterized by noticeable memory or thinking difficulties that do not interfere with daily life. The trial compares real tDCS treatment to a placebo (fake treatment) in both healthy older adults and those with MCI. Suitable candidates are right-handed individuals with normal cognitive function or a diagnosis of MCI, who do not have metal implants in their upper body or head. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research on brain health and memory improvement.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What prior data suggests that Transcranial Direct Current Stimulation (tDCS) is safe for use in this study?
Research shows that transcranial direct current stimulation (tDCS) is generally safe. Studies have found it can be used safely for up to 20 days and can significantly enhance thinking skills without major side effects. Although researchers continue to study tDCS, it is considered well-tolerated. Some people might experience mild tingling or itching on their scalp during treatment, but these sensations are usually temporary and harmless. Overall, available research reassures the safety of tDCS.12345
Why are researchers excited about this trial?
Researchers are excited about Transcranial Direct Current Stimulation (tDCS) for mild cognitive impairment because it offers a non-invasive approach that directly modulates brain activity. Unlike traditional treatments like medications, which often aim to manage symptoms by altering chemical balances in the brain, tDCS uses electrical currents to target specific brain areas, potentially enhancing cognitive function more precisely. This method is appealing because it may provide quicker results with fewer side effects, making it a promising alternative or complement to existing treatments.
What evidence suggests that Transcranial Direct Current Stimulation (tDCS) might be an effective treatment for mild cognitive impairment?
Research has shown mixed results for using transcranial direct current stimulation (tDCS) in people with mild cognitive impairment (MCI). Some studies suggest that tDCS can improve brain function and memory in individuals with Alzheimer's disease, but the benefits for those with MCI remain unclear. For instance, one study found no significant improvement in thinking skills with active tDCS compared to a sham treatment. However, another analysis indicated that tDCS might enhance brain function more than not using it at all. While some research suggests that tDCS can aid memory in MCI, the overall evidence remains weak. This trial will compare active tDCS with sham tDCS to further investigate its effects on MCI.34678
Who Is on the Research Team?
Alexandru Iordan, Ph.D
Principal Investigator
University of Michigan
Are You a Good Fit for This Trial?
This trial is for older adults who are either cognitively healthy or have mild cognitive impairment. Participants should be able to perform daily activities with minimal assistance and must not have any neurological disorders other than MCI.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive HD-tDCS treatment or sham for 20 minutes in 1 session
Follow-up
Participants are monitored for changes in brain activation and memory performance
What Are the Treatments Tested in This Trial?
Interventions
- Transcranial Direct Current Stimulation (tDCS)
Transcranial Direct Current Stimulation (tDCS) is already approved in United States, European Union, Canada for the following indications:
- Depression
- Stroke rehabilitation
- Chronic pain management
- Research use for various neurological and psychiatric conditions including autism spectrum disorder
- Depression
- Stroke rehabilitation
- Chronic pain management
- Research use for various neurological and psychiatric conditions including autism spectrum disorder
- Depression
- Stroke rehabilitation
- Chronic pain management
- Research use for various neurological and psychiatric conditions including autism spectrum disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor
Wayne State University
Collaborator
Alzheimer's Association
Collaborator